Aarti Drugs Ltd. - Research Center
524348 AARTIDRUGS Group (A) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Mar ' 22 | Sep ' 21 | Sep ' 20 | Mar ' 20 | Sep ' 19 | |
|---|---|---|---|---|---|
| Sales | 1,234.69 | 1,016.48 | 990.71 | 822.18 | 812.73 |
| Operating profit | 174.78 | 143.40 | 225.07 | 126.90 | 117.51 |
| Interest | 10.84 | 9.22 | 13.37 | 15.32 | 16.88 |
| Gross profit | 166.18 | 136.71 | 213.20 | 112.32 | 100.95 |
| EPS (Rs) | 11.75 | 9.30 | 15.32 | 35.76 | 22.48 |
Half yearly
results in details
| Mar ' 22 | Sep ' 21 | Sep ' 20 | Mar ' 20 | Sep ' 19 | |
|---|---|---|---|---|---|
| Other income | 2.24 | 2.53 | 1.50 | 0.74 | 0.32 |
| Stock adjustment | -25.77 | -52.17 | -6.66 | -21.99 | -31.94 |
| Raw material | 824.67 | 700.12 | 581.14 | 531.55 | 547.25 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 35.67 | 33.65 | 35.24 | 30.98 | 29.12 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 225.34 | 191.48 | 155.92 | 154.74 | 150.79 |
| Provisions made | - | - | - | - | - |
| Depreciation | 23.83 | 23.56 | 23.89 | 23.84 | 22.83 |
| Taxation | 33.50 | 27.00 | 46.50 | 13.55 | 25.75 |
| Net profit / loss | 108.85 | 86.15 | 142.81 | 83.31 | 52.37 |
| Extra ordinary item | - | - | - | 8.38 | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 92.60 | 92.60 | 93.20 | 23.30 | 23.30 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 14.16 | 14.11 | 22.72 | 15.43 | 14.46 |
| GPM (%) | 13.43 | 13.42 | 21.49 | 13.65 | 12.42 |
| NPM (%) | 8.80 | 8.45 | 14.39 | 10.12 | 6.44 |
Mutual Fund Selector
Find the fund that is right for you
© 2022 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis